https://www.selleckchem.com/pr....oducts/semaxanib-su5
Topical NGF eye drops (Cenegermin) were approved in 2015 as an orphan drug for the treatment of neurotrophic keratopathy (NK). The active substance Cenegermin is a recombinant form of human NGF (nerve growth factor). Presentation of efficacy and safety of Cenegermin for use in patients in an university real-life setting. Retrospective study at the Köln University Eye Hospital from 2017 to 2019 with n = 11 eyes. Average follow-up was 13.5 ± 7.1 months. Reasons for treatment were neurotrophic keratopathy stage II and III, clinica
Gefällt mir
Kommentar
Teilen
